Parnax Lab

₹106.99As of Sun 8 Nov 2026, 12:00 UTC

NSE:PARNAXLAB—

Country India

PE (Fwd) 8.892

TSR 10Y CAGR —

Div yield —

ROE —

Pharmaceutical Preparations

Beta (5Y) 0.20

PE TTM 10.43

TSR TTM —

Mkt cap ₹1.230B

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₹117

—

9.23%

—

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

2.486

Revenue₹B

—

1.630

1.676

1.888

1.878

2.486

2.700

11.12%

32.39

Revenue growth%

—

2.81

12.65

(0.54)

32.39

8.62

7.73

—

39.01

Gross margin%

—

42.47

44.25

43.56

46.70

39.01

39.07

43.56

8.89

Operating margin%

—

10.58

9.95

8.89

10.45

8.89

8.87

9.95

4.74

Net margin%

—

5.06

5.14

5.09

6.13

4.74

5.09

10.43

P/E ratio (avg)x

—

9.601

—

5.562

EV/EBITx

—

5.132

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

10.25

EPS₹

—

9.68

7.79

8.37

10.03

10.25

11.14

1.44%

—

2.24

EPS growth%

—

(19.60)

7.46

19.87

2.24

8.68

4.85

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

11.49

Shares (diluted)M

—

8.512

11.07

11.49

◌11.49

7.78%

—

Buyback yield%

—

(30.04)

(3.76)

—

◌—

(1.88)

—

D/E ratiox

—

1.229

Enterprise value₹B

—

1.229

—

LT debt₹M

—

Peers (US$12.48M)

Cap (US$)

Lactose (India) Limited

13.72M

19.01x

Makers Laboratories…

13.46M

16.92x

Godavari Drugs Limited

12.91M

23.79x

Hurum Co., Ltd.

12.83M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

3.986

3.405

Own earn%

—

Sh yield%

—

(1.88)

Owners

Insiders/Inst%

73.92

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

9–11

$1 testx

—

Incr. ROIC%

—

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic; herbal; and nutraceutical products.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹2.486B

11.12%

1.00×

Cost of revenue

₹1.516B

12.76%

1.06×

Operating expenses

₹748.8M

9.55%

0.94×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m